Trevi Therapeutics, Inc. (TRVI) Dividend History

Company News

• Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

  The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players working on 120+ pipeline drugs.

  GlobeNewswire Inc.

  Featured Companies: CTNM SNDX SRPT
• Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

  Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

  Zacks Investment Research
• Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick

  Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  Zacks Investment Research
• Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why

  Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

  Zacks Investment Research
• The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

  A more selective small-cap index has consistently outperformed the Russell 2000

  MarketWatch

  Featured Companies: ACRV ALLO ARLO ATNM CMPX CPRX CRBU DGII DVAX GPRE HLX IJR INZY IPSC IRWD IWM KPTI LCTX LGND MODV PAYO PCRX PRVA PTEN RCUS RLYB RNA SMTC SPY STOK TALO THRY TNYA VIGL VIR VOR XFOR XNCR XPER